GlassScriptPhysician profile
Rafay Mehdi
NPI 1881766293
$5,339.90
in general payments reported to CMS, 2019-2025
34 companies · $1,694 in 2025
The $1,694 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2020: $18.73 · 2021: $575 · 2022: $1,186 · 2023: $835 · 2024: $758 · 2025: $1,694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,286.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $949.49 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $606.91 | 2021-2025 | |
| Novo Nordisk INC | $601.18 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Biohaven Pharmaceutical Holding Company LTD. | $253.36 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $244.21 | 2022-2025 | Zoryve |
| Mylan Specialty L.P. | $243.65 | 2021-2023 | Yupelri |
| Pfizer INC. | $204.53 | 2019-2025 | |
| Tolmar, INC. | $193.48 | 2025 | Jatenzo |
| Corium, LLC | $166.53 | 2022-2023 | Azstarys |
| Idorsia Pharmaceuticals US INC | $162.50 | 2022-2023 | Quviviq |
| Nestle Healthcare Nutrition INC. | $157.66 | 2021-2022 | |
| Acerus Pharmaceuticals Corporation | $131.44 | 2022 | |
| Medtronic, INC. | $123.54 | 2023-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Exact Sciences Corporation | $116.95 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $116.43 | 2019-2025 | Lagevrio |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $113.83 | 2019-2025 | Rexulti |
| Lilly USA, LLC | $111.63 | 2025 | Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.61 | 2021-2022 | |
| Verity Pharmaceuticals INC. | $95.54 | 2024 | Tlando |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $90.94 | 2025 | Caplyta |
| Bausch Health US, LLC | $90.31 | 2022-2023 | Aplenzin |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.71 | 2024-2025 | Xifaxan |
| Biohaven Pharmaceuticals, INC. | $71.80 | 2021 | |
| Abbott Laboratories | $61.52 | 2022-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Gilead Sciences, INC. | $34.26 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.22 | 2023-2024 | Trintellix |
| Inspire Medical Systems, INC. | $32.52 | 2024 | Inspire |
| Biogen, INC. | $27.58 | 2024 | Skyclarys |
| Lundbeck LLC | $26.24 | 2025 | Rexulti |
| Sage Therapeutics, LLC | $24.28 | 2021 | |
| Becton, Dickinson and Company | $22.16 | 2025 | Bd Onclarity |
| Redhill Biopharma INC. | $20.30 | 2021 | |
| Genentech USA, INC. | $20.14 | 2021 | |
| Esperion Therapeutics, INC. | $16.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafay Mehdi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.